Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Cash from Operations (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Cash from Operations for 6 consecutive years, with 17233000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 19.81% to 17233000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 67851000.0, a 62.05% increase, with the full-year FY2025 number at 67851000.0, up 62.05% from a year prior.
  • Cash from Operations was 17233000.0 for Q4 2025 at Lexicon Pharmaceuticals, up from 23833000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 16993000.0 in Q2 2025 to a low of 55130000.0 in Q1 2024.
  • A 3-year average of 34044000.0 and a median of 39868000.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 74.39% in 2024, then soared 135.01% in 2025.
  • Lexicon Pharmaceuticals' Cash from Operations stood at 50548000.0 in 2023, then soared by 57.48% to 21491000.0 in 2024, then grew by 19.81% to 17233000.0 in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Cash from Operations are 17233000.0 (Q4 2025), 23833000.0 (Q3 2025), and 16993000.0 (Q2 2025).